SS&C price target raised to $60 from $58 at Morgan Stanley

Morgan Stanley raised the firm’s price target on SS&C to $60 from $58 and keeps an Equal Weight rating on the shares. Underlying trends across the business appear to be improving in line with the firm’s expectations, “aside from another blip in Healthcare,” says the analyst, who would like to see more consistent M&A or a bigger buyback in the absence of attractive targets.